Indivior Pharmaceuticals, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Indivior Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 95 | 1 | 99 | +5 |
| Shares | 67.5M | 167.7K | 64.8M | −2.56M (−3.8%) |
| Value | $1.38B | $0 | $1.03B | −$352.8M (−25.5%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Allianz Asset Management GmbH | 389,810 | $6.11M | 0.01% |
| Susquehanna International Group Ltd. | 200,000 | $3.22M | 0.81% |
| UBS Asset Management Americas Inc | 157,094 | $2.53M | 0.00% |
| Torno Capital, LLC | 70,500 | $1.14M | 0.12% |
| Campbell & CO Investment Adviser LLC | 63,521 | $995.5K | 0.08% |
| Caption Management, LLC | 49,000 | $789.9K | 0.08% |
| J. Safra Sarasin Holding AG | 36,000 | $564.3K | 0.01% |
| Two Sigma Advisers, LP | 21,100 | $340.1K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 20,022 | $322.8K | 0.02% |
| Tudor Investment Corp Et Al | 20,000 | $322.4K | 0.00% |
| Schonfeld Strategic Advisors LLC | 17,398 | $280.5K | 0.00% |
| XTX Topco Ltd | 15,427 | $248.7K | 0.02% |
| VELA Investment Management, LLC | 15,000 | $235.1K | 0.08% |
| Sage Rock Capital Management LP | 12,500 | $201.5K | 0.76% |
| Bank of New York Mellon Corp | 11,672 | $188.2K | 0.00% |
| Jump Financial, LLC | 11,098 | $178.9K | 0.00% |
| Two West Capital Advisors LLC | 10,500 | $169.3K | 0.16% |
| Lazard Asset Management LLC | 5,505 | $88.0K | 0.00% |
| ICA Group Wealth Management, LLC | 150 | $2.42K | 0.00% |
Sold out (14)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Quadrature Capital Ltd | 71,113 | $1.52M |
| Mirabella Financial Services LLP | 39,724 | $850.9K |
| Aviva PLC | 36,248 | $775.7K |
| Cannon Global Investment Management, LLC | 26,300 | $563.3K |
| Jane Street Group, LLC | 13,660 | $292.2K |
| Weiss Asset Management LP | 13,620 | $291.7K |
| Susquehanna International Securities, Ltd. | 12,257 | $262.5K |
| State of Tennessee, Treasury Department | 7,432 | $159.0K |
| First Manhattan Co | 2,315 | $49.6K |
| New York State Common Retirement Fund | 659 | $14.1K |
| Advisor Group Holdings, Inc. | 177 | $3.79K |
| West Branch Capital LLC | 100 | $2.14K |
| Bell Investment Advisors, Inc | 22 | $472 |
| Polar Capital Holdings Plc | 285,077 | – |
Not filed for Q2 2024 yet (1)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 167,722 | – |